Table 1 Drugs that were selected for testing using three methods based on GCN analysis and MatchMaker predictions.

From: Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease

Method 1: Drug-target GCN analysis

Method 2: PolypharmDB query for 10 single GCN-target panels

Method 3: PolypharmDB query for one 10 GCN-targets panel

Drug

Target

Drug

Target

Drug

Panel of Targets

Bucladesine

PRKACA

Bortezomib

IRAK4

Anidulafungin

UGGT2, SDF2,

NLRX1, MOGS,

HEPACAM, IRAK4,

ADAM15,

CD46, LILRA3,

and CHPF2

Cinnarizine

CACNA1C

Cefotiam

TARS2

Capmatinib

 

Doxycycline

PADI4

Dapagliflozin

UGGT2

Bortezomib

 

Eflornithine

SLC25A21

Degarelix

CD46

Dapagliflozin

 

Flucytosine

DNMT1

Fosamprenavir

ADAM15

Fosamprenavir

 

Glyburide

ABCA1

Gentamicin

HEPACAM

Glipizide

 

Nelarabine

POLA1

Glipizide

ADAM15

Palbociclib

 

Opicapone

COMT

Palbociclib

IRAK4

Streptozocin

 

Otilonium

CACNA1C

Polidocanol

MOGS

Tofacitinib

 

Simvastatin

ITGB2

Saquinavir

CD46

  
  

Streptozocin

HEPACAM

  
  

Sugammadex

MOGS

  
  

Telithromycin

CD46

  
  

Tofacitinib

IRAK4

  
  1. Top 26 drug candidates were selected based on GCN and MatchMaker predictions as described in Fig. 1 and in Materials and Methods. Cefotiam, under Method 2, was selected from the list of 10 top ranking candidates for TARS2, which was among the top 100 human proteins predicted to be associated with COVID-19 through target-only GCN analysis, but was not prioritized in the initial selection of top 10 targets described above. Drug candidates that were selected using Method 3 and were also predicted by Method 2 are shown in grey font and italics.
Back to article page